| Name | Kartogenin |
| Description | Kartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes. |
| Cell Research | For the cell viability assay, fibroblasts are seeded on six-well plates, followed by Kartogenin or DMSO treatment. According to the manufacturer's instructions, cell viability and viability are assessed by AlamarBlue assay.(Only for Reference) |
| In vitro | Kartogenin promotes type I collagen synthesis in dermal fibroblasts by activating the Smad4/Smad5 pathway, without exhibiting significant cytotoxicity on the activity, morphology, and survival of fibroblasts. Additionally, by enhancing the nuclear localization of CBFβ, Kartogenin induces differentiation of hMSCs into chondrocytes and protects articular chondrocytes. |
| In vivo | Kartogenin at a concentration of 100 nM stimulates collagen synthesis in the dermis of mice. Additionally, it promotes the growth of skeletal limbs and the development of synovial joints in mice. Concentrations of 10 μM and 100 μM Kartogenin respectively enhance cartilage repair in mouse models of osteoarthritis (OA) induced by collagenase VII and surgically. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : <1 mg/mL
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.3 mM), Sonication is recommended.
DMSO : 41.67 mg/mL (131.31 mM), Sonication is recommended.
Ethanol : 18 mg/mL (56.72 mM), Heating is recommended.
|
| Keywords | Transforming growth factor beta | TGF-β/Smad | TGFβ | TGF-beta/Smad | TGFbeta/Smad | TGF-beta | TGFbeta | TGF-b/Smad | TGFb | stem | Smad5 | Smad4 | Smad | osteoarthritis | mesenchymal | Kartogenin | Inhibitor | inhibit | human | differentiation | chondrocytes | cells |
| Inhibitors Related | Trimethylamine N-oxide | Melamine | SB-431542 | Hydrochlorothiazide | Hippuric acid | Chromenone 1 | Pirfenidone | A 83-01 | Suberic acid | Cetrimonium bromide | Galunisertib | Alantolactone |
| Related Compound Libraries | Osteogenesis Compound Library | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | PPI Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | TGF-beta/Smad Compound Library |
United States
